Company intelligence / Profile preview
Beam Therapeutics
Cambridge, Massachusetts, United States of Americabeamtx.com ↗
- Ownership
- Public · BEAM
- Employees
- ~483
- Development stage
- Phase 1
01
Overview
Beam has reported initial clinical data from the BEACON trial for BEAM-101 in sickle cell disease, showing all four patients in the efficacy cohort achieved fetal hemoglobin levels above 70% at 1-6 months follow-up. The company has also advanced BEAM-302 for alpha-1 antitrypsin deficiency and BEAM-301 for glycogen storage disease type 1a into clinical trials[6][7].
- Therapeutic areas
- OncologyMetabolic DisordersOphthalmologyHematologyRare Diseases
- Modalities
- Gene editingbase editingprime editingnuclease editingRNA editing
- Industry
- Biotech
02
Drug pipeline
16 assets15 more assets in the full pipeline.
Request access →03
Partnerships
04
Financials
- Market cap
- $2.8B
- Total revenue
- $490K
- Enterprise value
- $1.9B
Beyond the preview
Go deeper on Beam Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beam Therapeutics.